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The American Joint Committee on Cancer (AJCC) staging of cutaneous melanoma is a continuously evolving system.
The identiﬁcation of increasingly more accurate prognostic factors has led to major changes in melanoma staging over
the years, and the current system described in this review will likely be modiﬁed in the near future. Likewise, application
of new imaging techniques has also changed the staging work-up of patients with cutaneous melanoma. Chest and
abdominal computed tomography (CT) scanning is most commonly used for evaluation of potential metastatic sites in
the lungs, lymph nodes and liver, and is indicated in patients with new symptoms, anaemia, elevated lactate
dehydrogenase or a chest X-ray abnormality. CT scans should be restricted to patients with high-risk melanoma (stage
IIC, IIIB, IIIC and stage IIIA with a macroscopic sentinel lymph node). Magnetic resonance imaging (MRI) of the brain is
a mandatory test in patients with stage IV, optional in stage III and not used in patients with stage I and II disease.
Positron emission tomography (PET)/CT is more accurate than CT or MRI alone in the diagnosis of metastases and
should complement conventional CT/MRI imaging in the staging work-up of patients who have solitary or
oligometastatic disease where surgical resection is most relevant.
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the current AJCC staging system
The AJCC staging system is based on evaluation of the primary
tumour (T) and the presence or absence of regional lymphatic
(N) and distant metastases (M). The system separates patients
into four groups (Tables 1 and 2).
Stage I is limited to patients with low-risk primary
melanomas without evidence of regional or distant metastases,
and is divided into stages IA and IB. Stage IA includes primary
lesions £1 mm thick, without ulceration of the overlying
epithelium or invasion of the reticular dermis or subcutaneous
fat (Clark level IV or V). Stage IB includes primary lesions £1
mm thick with epithelial ulceration or invasion into Clark level
IV or V. It also includes primary lesions ‡1 mm and £2m m
thick without ulceration or invasion into Clark level IV or V.
Stage II includes high-risk primary tumours, without
evidence of lymphatic disease or distant metastases, and is
divided into three subcategories. Stage IIA includes lesions >1
mm and £2 mm thick with ulceration of the overlying
epithelium and those >2 mm and £4 mm thick without
epithelial ulceration. Stage IIB lesions are >2 mm and £4m m
thick with epithelial ulceration or >4 mm without ulceration.
Stage IIC consists of primary lesions >4 mm with epithelial
ulceration.
Stage III includes lesions with pathologically documented
involvement of regional lymph nodes or the presence of in-
transit or satellite metastases. Patients with one, two to three, or
four or more affected lymph nodes are classiﬁed as having N1,
N2 and N3 disease, respectively (Tables 1 and 2). Patients with
in-transit or satellite metastases are classiﬁed as having N2
disease if lymph node involvement is not present, and as having
N3 disease if lymph node involvement is present. In addition,
microscopic versus macroscopic lymph node involvement is
further subdivided as, for example, N1a versus N1b category,
respectively. The presence of ulceration in the primary tumour
remains an independent negative prognostic factor among
patients with stage III disease, particularly those with
microscopically involved nodes. Using these parameters,
patients with stage III disease are divided into three
subcategories: (a) stage IIIA includes patients with one to three
microscopically involved lymph nodes (N1a or N2a) and with
a non-ulcerated primary tumour; (b) stage IIIB includes
patients with one to three microscopically involved lymph
nodes (N1a or N2a) and with an ulcerated primary tumour, or
patients with one to three macroscopically involved lymph
nodes (N1b or N2b) and with a non-ulcerated primary tumour,
or patients with in-transit and/or satellites without metastatic
lymph nodes (N2c); (c) stage IIIC includes patients with four
or more affected lymph nodes, matted lymph nodes or the
presence of in-transit metastases or satellite lesions in
conjunction with lymph node involvement (N3), or patients
with one to three macroscopically involved lymph nodes (N2b)
and with an ulcerated primary tumour. Patients with clinical
evidence of regional lymph node metastasis without a full
regional lymph node dissection are classiﬁed as clinical stage
III, and no further staging is applied.
Stage IV is deﬁned by the presence of distant metastases, and
patients are divided into three subcategories based on the
metastasis location: M1a is limited to distant skin,
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metastases; and M1c involves all other visceral sites. In
addition, the presence of elevated serum lactate dehydrogenase
(LDH) in conjunction with any distant metastasis classiﬁes as
M1c disease.
evolution of the staging system
The key new features of the current 2002 AJCC staging system
when compared with the previous 1997 system include the
following: (a) tumour thickness rather than level of invasion as
a primary determinant for staging; (b) ulceration of the
primary tumour as a highly signiﬁcant and independent
negative prognostic factor; (c) grouping together satellite and
in-transit metastases as manifestations of lymphatic
involvement rather than as an extension of the primary
tumour; (d) number of lymph node metastases as a more
reliable and reproducible predictor of prognosis than the size of
the involved lymph nodes—the number of lymph node
metastases is used to divide patients with stage III disease, and
lymph node involvement is further subdivided into micro- or
macrometastatic; (e) separation of lung metastases from other
visceral sites of involvement, based on an observed longer
survival; and (f) elevated serum LDH as a negative prognostic
factor for patients with metastatic disease.
The AJCC Staging Task Force meets regularly to revise the
staging system; the committee recently discussed the
incorporation of mitotic rate, an important prognostic factor
particularly in thin lesions, into the staging criteria. This
parameter will likely be incorporated into the next staging
system.
imaging techniques and laboratory
investigations in staging work-up
Since the prognosis for patients with melanoma is determined
by histology of the primary tumour and by the presence and
extent of metastatic disease, imaging studies using radiographic
and nuclear medicine techniques are an important component
of the evaluation of patients with both localised and advanced
melanoma (Table 3). However, the staging evaluations used at
the time of initial diagnosis are often excessive. Few established
guidelines for melanoma deﬁne the appropriate tests for the
initial evaluation and subsequent follow-up.
computed tomography scanning
Besides skin, subcutaneous tissue and lymph nodes, the lung is
the most common site of melanoma metastases. Contrast-
Table 1. TNM classiﬁcation of cutaneous melanoma (adapted from [1])
Tumour (T) classiﬁcation
TX Primary tumour cannot be assessed (e.g. shave
biopsy, regressed primary)
Tis Melanoma in situ
T1 £1.00 mm
T1a Without ulceration or level II/III
T1b With ulceration or level IV or V
T2 1.01–2.00 mm
T2a Without ulceration
T2b With ulceration
T3 2.01–4.00 mm
T3a Without ulceration
T3b With ulceration
T4 >4.00 mm
T4a Without ulceration
T4b With ulceration
Node (N) classiﬁcation
N1 One lymph node
N1a Micrometastases
a (clinically occult)
N1b Macrometastases
b (clinically apparent)
N2 Two to three lymph nodes
N2a Micrometastases
a
N2b Macrometastases
b
N2c In-transit met(s)/satellite(s) without metastatic
lymph nodes
N3 Four or more lymph nodes, metastatic or matted, or
in-transit met(s)/satellite(s) with metastatic
lymph node(s)
Metastasis (M) classiﬁcation
M1a Distant skin, subcutaneous or lymph node
metastases, normal LDH
M1b Lung metastases, normal LDH
M1c All other visceral metastases, normal LDH; any
distant metastases, elevated LDH
aMicrometastases are diagnosed after elective or sentinel lymphadenectomy.
bMacrometastases are clinically detectable lymph node metastases
conﬁrmed by therapeutic lymphadenectomy, or lymph node metastases
exhibiting gross extracapsular extension.
Table 2. AJCC 2002 stage groupings for cutaneous melanoma (adapted
from [1])
Stage Clinical stage grouping Pathologic stage grouping
0 Tis N0 M0 pTis N0 M0
IA T1a N0 M0 pT1a N0 M0
IB T1b N0 M0 pT1b N0 M0
T2a N0 M0 pT2a N0 M0
IIA T2b N0 M0 pT2b N0 M0
T3a N0 M0 pT3a N0 M0
IIB T3b N0 M0 pT3b N0 M0
T4a N0 M0 pT4a N0 M0
IIC T4b N0 M0 pT4b N0 M0
III Any T N1–3 M0
IIIA pT1–4a N1a M0
pT1–4a N2a M0
IIIB pT1–4b N1a M0
pT1–4b N2a M0
pT1–4a N1b M0
pT1–4a N2b M0
pT1–4a/b N2c M0
pT1–4b N1b M0
IIIC pT1–4b N2b M0
Any T N3 M0
IV Any T Any N M1 Any T Any N M1
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reliable radiographic method for evaluating intrathoracic
metastases [4–6]. CT also is superior to a chest X-ray in
demonstrating the mediastinal and hilar adenopathy that often
accompanies parenchymal lesions and/or the presence of
lymphatic spread. CT is more speciﬁc than plain radiographs in
the evaluation of lesions in the bone, and is particularly useful
for the detection of purely lytic lesions not apparent by
radionuclide bone scan [7]. CT has similar speciﬁcity to
ultrasound for the detection of abdominal metastases, but its
sensitivity is better (85% compared with 57%) [8].
magnetic resonance imaging
While CT and ultrasound are the preferential procedures for
imaging the liver, magnetic resonance imaging (MRI) may be
useful to differentiate between benign lesions such as
haemangiomas and melanoma metastases [9–11]. MRI is also
superior in delineation of vascular involvement and
identiﬁcation of additional hepatic lesions. It is the best
modality for evaluating signal abnormalities in bone marrow
and detecting accompanying features such as haemorrhage or
soft-tissue masses but has relatively low speciﬁcity. MRI is
signiﬁcantly more sensitive than CT for the detection of
metastatic disease to the brain [12], and also provides more
detailed information about possible involvement of the spinal
cord and leptomeninges.
positron emission tomography scan and PET/CT
The role of positron emission tomography (PET) and PET/CT
in the management of patients with melanoma is rapidly
evolving. PET/CT appears to be superior to stand-alone PET
[13–16], and is rapidly replacing the use of PET alone for the
detection of metastatic disease.
In patients with advanced melanoma, PET/CT is more
sensitive than anatomic imaging modalities, such as CT or
MRI, and at least equally speciﬁc [17–22]. Sensitivity is highest
(‡90%) for metastases that are >1 cm in diameter, but tumour
deposits as small as 0.6 cm can be reliably seen in areas of low
background activity. In a retrospective study with 250 patients,
PET/CT scans detected signiﬁcantly more visceral and non-
visceral metastases than either PET alone or CT alone (98.7%,
88.8% and 69.7%, respectively) [21]. In that series, PET/CT
permitted more accurate staging of distant metastases than
either PET or CT alone (98% compared with 93% and 84%,
Table 3. Common practices for stage-speciﬁc and survival-related stage
work-up
Pathologic stage
0 I II III IV
ABABCA B C
Ultrasound nodal basin E E E E E E E
Chest X-ray E E E E W W W W
Ultrasound abdomen E E E E E E E E
LDH and S100B E E E E E E E W
CT chest, abdomen, pelvis E E W W W
Brain MRI W W W
PET or PET/CT E E R
E, used in various European countries [2, 3] but unproven utility; W,
commonly used worldwide but without proven impact on overall survival
in the total melanoma population; R, most useful in patients with
potentially resectable disease.
Figure 1. Ultrasound image of a metastatic lymph node. The lesion reveals the typical appearance of a lymph node metastasis during follow-up showing
a balloon shape, and irregular and mostly peripherally located hyper-perfusion corresponding to neo-angiogenesis. The suspicious lymph node can easily be
evaluated with FNAC.
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staging regional lymph nodes (98% compared with 86%).
Fluorodeoxyglucose (FDG)-PET imaging alone has a lower
sensitivity than PET/CT (43% compared with 97%) and is less
sensitive for the detection of melanoma metastases in the liver
and brain compared with that in other sites [17, 22, 23].
New data indicate that PET/CT may be the most accurate test
for the diagnosis of bone metastases [7, 24, 25]. Overall, PET/
CT is more accurate than CT or MRI alone in the diagnosis of
metastasis, but there is no convincing evidence that the
improved accuracy of PET/CT over CT scanning alone
improves patient outcome [26]. Unfortunately, PET and PET/
CT are not sufﬁciently available or reimbursed in many
countries.
lymph node ultrasound
Nodal metastases are frequently the initial manifestation of
metastatic spread [27]. Complete and accurate determination
of nodal status is important not only for prognosis but also for
decision-making regarding sentinel lymph node biopsy (SNB)
and adjuvant therapy.
Physical examination is an inaccurate predictor of nodal
metastases: 20% of clinically node-negative patients have
metastatic deposits, whereas 20% of those who are clinically
node-positive have pathologically negative nodes. Furthermore,
CT scanning is insensitive to the presence of small nodal
metastases and also is complicated by false-positive results [28].
Several studies show the beneﬁt of nodal ultrasound as
compared with palpation and in combination with ﬁne needle
aspiration cytology (FNAC) [29, 30]. Ultrasound is routinely
used, especially in some European countries, in the staging
work-up before SNB and during follow-up. Sensitivity for the
detection of a positive sentinel node by ultrasound before
a surgical procedure ranges between 39% and 79%, and
speciﬁcity is 100%. In patients with a positive ﬁnding by
cytology, SNB can be avoided by directly performing
therapeutic lymph node dissection.
lymphoscintigraphy and SNB
The pattern of tumour cell spread to sentinel lymph nodes
(SLNs) can be most accurately demonstrated by a combination
of lymphoscintigraphy and SNB. When performed correctly,
the SNB can provide important information that directly
inﬂuences patient management and prognosis [31–36]. Besides
histopathology of the primary melanoma, SNB is the most
important staging tool. In experienced hands, the false-negative
rate for the SLN procedures is typically £5% [37, 38]. Problems
are often encountered with head and neck lesions where the
detection rate is lower.
bone scintigraphy
Bony metastatic disease may appear on a plain radiograph [39].
Although most metastases are lytic, the activity of osteoblasts at
the site of a bony metastasis can often be detected by bone
scintigraphy months before changes are seen on plain
radiographs [40].
Despite its sensitivity, bone scanning is not routinely ordered
in patients with primary melanoma unless symptoms indicating
bone metastases are present. The low speciﬁcity of this
technique, combined with the low incidence of metastases to
the bone early in the disease, results in an unacceptable number
of false-positive ﬁndings.
If bone pain develops in a patient with melanoma and plain
radiographs are negative, the bone scan offers a sensitive test to
help rule out metastatic disease.
Figure 2. Ultrasound of a benign lymph node. Both oval-shaped lesions show an enlarged but normal reactive lymph node with central echoes in B-mode
and peripheral lack of echoes according to the parenchyma and centrally located perfusion. These lesions can safely be validated by ultrasound alone.
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LDH and S100B have been found more valuable than any other
blood serum markers. LDH has been widely accepted as
a prognostic marker in stage IV and was reported to be suitable
to detect liver metastases, although its increased concentration
is not very speciﬁc for that kind of metastasis. Several authors
found increased serum LDH in most patients with progressive
distant metastases. An increased concentration of LDH was
found to be a ﬁrst sign of metastases in 12% of patients [41].
However, an increase in LDH can be caused by many other
factors, and, in general, determination of LDH has low
sensitivity and speciﬁcity for the detection of distant melanoma
metastases.
S100B is found in primary melanoma and is positively
correlated with the invasiveness of the tumour. It has been
shown that S100B levels correlate with clinical staging, the
extent of metastatic spread and disease progression [42, 43].
The value of measuring serum S100B for staging work-up and
follow-up is controversial, especially in the early stages of
melanoma, as its sensitivity ranges between 30% and 60% and
depends on the stage of the disease [44]. The analysis of both
serum parameters is fairly inexpensive when compared with
most imaging techniques.
staging work-up in different clinical
stages
stage I and IIA/B
Melanoma has the potential to metastasise to any organ:
common sites of dissemination include the skin, subcutaneous
tissues, lymph nodes, liver, bone, lung, brain and visceral
organs. Because of this metastatic potential, patients with
localised (stage I and II) primary melanoma commonly
undergo unnecessary, extensive radiological evaluations
searching for distant metastases.
A routine physical examination, including a full skin
assessment and palpation of regional lymph nodes, and taking
the patient’s history is the basis of every staging work-up in
cutaneous melanoma. Palpation and patient self-examination
remain the most important tools in the detection of
locoregional metastases. Up to 70% of ﬁrst recurrences of
primary melanomas are locoregional [45], and most imaging
techniques do not evaluate the regional area very well.
Asymptomatic patients with clinical stage I or II lesions
should be differentiated based on their risk of relapse. In
patients with a lesion <1.0 mm thick, an imaging work-up is
not recommended, since the cure rate is >90% and the
likelihood of detecting asymptomatic metastases at the time of
primary diagnosis is virtually zero. Most imaging studies are
not indicated even in patients with primary melanoma thicker
than 1.0 mm, since the detection of distant metastases is also
rare. In these patients, SNB is the most important staging tool
and should be performed routinely [1].
Although a chest X-ray is routinely ordered in patients with
stage I and II melanoma, it serves primarily as baseline
information for future comparison as the detection yield of
metastatic disease is negligible. For instance, in a series of 876
asymptomatic patients in stage I/II, only one patient (0.1%)
had a true-positive chest ﬁlm demonstrating pulmonary
metastases; in contrast, false-positive tests occurred in 15% of
cases [46].
Despite the aggressive nature of melanoma and the potential
for early disease dissemination, extensive imaging (e.g. CT of
the chest, abdomen, pelvis and brain) of asymptomatic patients
with stage I or II melanoma is usually not indicated, since the
detection rate is low and the frequency of false-positive ﬁndings
is unacceptably high (10–20%) [25, 28, 47].
Recent studies using ultrasound of the regional lymph node
basin showed convincingly that this technique is an inexpensive
tool for detection of early lymph node metastasis [48]. We
recommend the inclusion of lymph node ultrasound in staging
investigations, which offers the opportunity to perform
ultrasound-guided FNAC for cytological evaluation. Since
physical examination is an inaccurate predictor of nodal
metastases and 20% of clinically node-negative patients have
metastatic deposits, SNB can be avoided in patients with
suspicious nodal lesions conﬁrmed by FNAC [29, 30]. These
patients should directly undergo complete lymph node
dissection.
PET has not been useful in the staging work-up of patients
with stage I and II disease due to its low sensitivity for regional
lymphatic disease and occult metastases [49–51]. In addition,
there is a relatively high rate of false-positive examinations. In
1% of patients, PET may detect an incidental second primary
tumour [52].
Serum S100B and LDH have limited sensitivity and
speciﬁcity, especially in the early stages of melanoma. These
blood tests may provide baseline information for patients with
primary melanoma >1.0 mm Breslow depth.
Patients with a melanoma thicker than 4.0 mm and with an
ulcerated primary tumour (stage IIC) have an unfavourable
outcome with a median 5-year survival of 40%, which is
lower than that of patients with stage IIIA disease. We
recommend a similar staging work-up for these patients to that
for those with stage IIIB melanoma.
stage IIC and III
A similarly poor clinical outcome is observed for stages IIC and
III. Patients with positive SLNs often undergo comprehensive
imaging evaluation before completing lymphadenectomy, or
following surgery when considered for an adjuvant therapy or
a trial. However, despite the frequent use of such studies,
routine staging with CT, MRI or PET does not appear to be
useful in this setting, as the techniques usually do not show
early metastatic disease. The low frequency of detectable
metastases found with extensive imaging is illustrated by three
large, single-institution series; in these trials, the detection rate
of occult metastases with chest CT, abdomen CT, or brain CT
or MRI was between 0.5% and 3.7%. All metastasis-positive
patients had macrometastatic disease in the sentinel node and
thick, or thick and ulcerated primary lesions. If CT imaging had
been restricted to those patients, the true-positive rate would
have been up to 13%. The false-positive rate was up to 12% [47,
53, 54]. This indicates that, for the purpose of a staging work-
up, patients with positive SLNs should be further differentiated
into a group with macroscopic nodal disease and a group with
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imaging work-up.
Patients with stage IIC and III melanoma, including those
with local, satellite, in-transit or macroscopic nodal disease,
have a >50% risk of systemic recurrence [55]. For these
patients, a complete blood analysis, serum LDH and chest X-
ray for future reference should be obtained. Although advanced
imaging studies (CT, MRI, PET) have a relatively low yield for
detecting distant metastases in asymptomatic stage IIC and III
patients, metastases are detected more frequently than in those
with stage I and II disease, indicating that additional imaging
studies are warranted. Patients who develop a second
locoregional recurrence represent a higher risk subset and
should undergo staging evaluations as if they had distant
metastases.
CT imaging of the chest and abdomen is commonly
performed in patients with locoregional disease. Although the
yield of these tests (particularly abdominal CT) in detecting
distant metastases in asymptomatic patients is low, they often
identify false-positive abnormalities and thereby function as an
important baseline for future studies in this high-risk
population. CT scanning of the pelvis is generally performed
for patients with a locoregional recurrence below the waist [56,
57], and the neck is generally imaged for a recurrence in the
head and neck region. Nodal ultrasound is an alternative to CT
scanning of the head and neck region.
The necessity of performing routine brain imaging in
asymptomatic patients with advanced locoregional disease is
controversial. Some clinicians perform the procedure only in
symptomatic patients to rule out central nervous system (CNS)
involvement, while others recommend brain imaging before
deﬁnitive local therapy in accordance with a report showing
a rate of asymptomatic CNS metastases as high as 6% [58].
PET/CT is widely used at many centres in the USA, and the
role of PET/CT in clinical stage III melanoma is rapidly
evolving [59]. However, unresolved issues remain regarding the
optimal technique (use of p.o. or i.v. contrast, respiratory
gating). Like CT or PET alone, the interpretation of PET/CT is
complicated by false-negatives, false-positives and the
identiﬁcation of second primaries. No studies assess the value
of integrated PET/CT imaging in patients with the disease
limited to a positive sentinel node. PET/CT may be particularly
valuable for patients with regionally advanced disease, where
identiﬁcation of additional regional disease would alter planned
surgical strategy. In addition, PET/CT may be used for
evaluation of suspicious or equivocal ﬁndings identiﬁed by
conventional imaging.
The sensitivity of serum S100B in patients with stage III and
IV melanoma ranges between 30% and 60%, while the
speciﬁcity is 90%. Therefore, baseline examination of LDH
and S100B may be valuable in that group.
clinical stage IV melanoma
Detection of early stage IV metastasis plays a role in palliative
care but has not been associated with a better treatment
outcome. Patients with known systemic metastases (stage IV)
should be evaluated more comprehensively because the
likelihood of detecting additional asymptomatic lesions is high.
These patients should be staged with MRI of the brain and CT
of the chest and abdomen. CT of the pelvis is indicated for
patients with a history of primary tumours below the waist or
with symptoms indicating metastatic involvement. Other
imaging studies should be ordered based on symptoms
(e.g. bone scan for patients with bone pain, small-bowel
follow-through for patients with anaemia indicating
iron-deﬁciency). Serum LDH should be determined in all
patients as it carries prognostic signiﬁcance (Table 1).
PET scans often show a greater sensitivity for the detection of
metastases when compared with conventional radiographic
studies [17, 21, 60]. In a series of 100 patients with stage IV
disease, 415 metastatic lesions were evaluated with PET and
routine CT scans [60]. The PET scan detected 93% of lesions
and, in 20 patients, it detected 24 metastases up to 6 months
earlier than conventional imaging or physical examination [60].
However, PET without concurrent CT may only complement
routine imaging studies rather than replace them. Therefore, we
generally recommend complementing conventional CT/MRI
imaging with integrated PET/CT in the staging work-up of
patients who have solitary or oligometastatic disease where the
issue of surgical resection is most relevant.
conclusion
Melanoma can metastasise to a number of sites throughout the
body, and the route and pattern of metastatic disease is
unpredictable. The AJCC staging system provides the basis for
identiﬁcation of the risk of relapse and a guide to patient
management. The AJCC Staging Task Force meets regularly to
revise the staging system and to make it more accurate; mitotic
rate will likely be incorporated into the staging system in the
near future.
Since up to 70% of the ﬁrst recurrence is found in the
locoregional area, routine physical examination, including full
skin assessment and palpation of regional lymph nodes,
remains the most important tool to detect locoregional
metastases. In several countries in Europe, ultrasound of the
nodal basin and abdominal ultrasound are part of the routine
staging work-up. However, more data are needed to prove the
value of these studies.
Lymphoscintigraphy and SNB are integral components of
primary management and staging for patients with cutaneous
melanoma >1.0 mm thick who are clinically node negative.
Ultrasound of the nodal basin in combination with ﬁne needle
aspiration cytology before SNB can avoid SNB by sending the
patient directly to radical lymph node dissection in the case of
a positive cytological ﬁnding.
Investigations that include cost–efﬁcacy analyses need to be
carried out to formally prove the beneﬁt of modern imaging
approaches. Chest and abdominal CT scanning is most
commonly used for evaluation of potential metastatic sites in
the lungs, lymph nodes and liver, and is indicated in any
patient with new symptoms, physical ﬁndings, anaemia,
elevated LDH or a chest X-ray abnormality. CT scans should be
restricted to patients with high-risk melanoma (stage IIC, IIIB,
IIIC and stage IIIA with a macroscopic SLN).
MRI of the brain is the procedure of choice for symptoms
related to the CNS. It is a mandatory test in patients with stage
Annals of Oncology Article
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patients with stage I and II disease. Although early detection of
brain metastases may identify a limited number of patients who
are eligible for more aggressive local therapies, no available data
demonstrate that screening for brain metastases results in
a survival beneﬁt for patients.
We recommend that bone scintigraphy should not be part of
a routine stage work-up unless there is clinical suspicion of
bone metastases.
The role of PET/CT in the evaluation and management of
patients with advanced locoregional or metastatic disease is
evolving rapidly. Overall, PET/CT is more accurate than CT or
MRI alone in the diagnosis of metastases. PET/CT is most
useful for identifying all metastatic sites of disease before
embarking on a metastasectomy of an apparently isolated
lesion, or for clarifying the nature of a suspicious lesion
identiﬁed by the CT scan.
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